News with Multimedia
-
FICO Survey: Alarming Acceptance of 'Liar Loans' Among Thai Consumers
09/24/2024 - 10:00 AM
-
Rumble Boxing Hits Asia: Premier Fitness Boutique Unveils First Studio in Japan
09/24/2024 - 01:00 AM
-
NIPPON KINZOKU: Welded Drawn Pipe Surpassing Seamless Pipe Introduction of “FINE PIPE” Series
09/23/2024 - 11:01 PM
-
Copeland Appoints New Leader for India, Middle East and Africa
09/23/2024 - 09:00 PM
-
The Winners of the 2024 International Quant Championship
09/23/2024 - 09:00 PM
-
Conexus MedStaff Announces New Partnership with Fairplay for All Foundation, to Invest in Youth Scholars in the Philippines
09/23/2024 - 10:02 AM
-
Leading Global Aviation Lawyer Paul Jebely Joins Sterlington as Partner and Vice Chair, International
09/23/2024 - 04:28 AM
-
VinFast présente ses résultats financiers non audités pour le deuxième trimestre de l'année 2024
09/21/2024 - 07:16 PM
-
Riassunto: Neu-REFIX Beta glucan riceve dall'FDA statunitense le designazioni di farmaco orfano e per malattia rara pediatrica per il trattamento della distrofia muscolare di Duchenne
09/21/2024 - 01:40 AM
-
Neu-REFIX Beta葡聚糖獲美國食品藥物管理局的罕見兒科疾病認定和孤兒藥認定,用於治療裘馨氏肌肉失養症
09/21/2024 - 01:37 AM
-
Neu-REFIX Beta葡聚糖获得美国FDA罕见儿科疾病和孤儿药认定,可用于治疗杜氏肌营养不良症
09/21/2024 - 01:33 AM
-
Samenvatting: Neu-REFIX Beta glucan ontvangt van de Amerikaanse FDA de benaming voor zeldzame ziekten bij kinderen en het statuut weesgeneesmiddel voor de behandeling van Duchenne spierdystrofie
09/21/2024 - 01:26 AM
-
El betaglucano Neu-REFIX recibe las designaciones de enfermedad pediátrica rara y medicamento huérfano de la FDA de EE. UU. para el tratamiento de la distrofia muscular de Duchenne
09/21/2024 - 01:23 AM
-
VinFast Reports Unaudited Second Quarter 2024 Financial Results
09/20/2024 - 09:28 PM
-
Neu-REFIX beta-glucano recebe designações de doença pediátrica rara e medicamento órfão da FDA dos EUA para tratamento da distrofia muscular de Duchenne
09/20/2024 - 07:04 PM